Review

Repair Mechanisms of the Neurovascular Unit after Ischemic Stroke with a Focus on VEGF

Sunhong Moon 1, Mi-Sook Chang 2,*, Seong-Ho Koh 3 and Yoon Kyung Choi 1,*

1 Department of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Seoul 05029, Korea; msh9504@konkuk.ac.kr
2 Department of Oral Anatomy, Seoul National University School of Dentistry, Seoul 03080, Korea; mschang@snu.ac.kr
3 Department of Neurology, Hanyang University Guri Hospital, Guri 11923, Korea; ksh213@hanyang.ac.kr
* Correspondence: ykchoi@konkuk.ac.kr; Tel.: +82-2-450-0558; Fax: +82-2-444-3490

Abstract: The functional neural circuits are partially repaired after an ischemic stroke in the central nervous system (CNS). In the CNS, neurovascular units, including neurons, endothelial cells, astrocytes, pericytes, microglia, and oligodendrocytes maintain homeostasis; however, these cellular networks are damaged after an ischemic stroke. The present review discusses the repair potential of stem cells (i.e., mesenchymal stem cells, endothelial precursor cells, and neural stem cells) and gaseous molecules (i.e., nitric oxide and carbon monoxide) with respect to neuroprotection in the acute phase and regeneration in the late phase after an ischemic stroke. Commonly shared molecular mechanisms in the neurovascular unit are associated with the vascular endothelial growth factor (VEGF) and its related factors. Stem cells and gaseous molecules may exert therapeutic effects by diminishing VEGF-mediated vascular leakage and facilitating VEGF-mediated regenerative capacity. This review presents an in-depth discussion of the regeneration ability by which endogenous neural stem cells and endothelial cells produce neurons and vessels capable of replacing injured neurons and vessels in the CNS.

Keywords: stroke; vascular endothelial growth factor (VEGF); blood–brain barrier (BBB); stem cell; gaseous molecule; regeneration

1. Overview of Repair Mechanisms Following Brain Damage

Ischemic stroke, which accounts for 87% of all stroke cases, results from a sudden cessation of adequate amounts of blood supply to parts of the brain. The vascular system plays a critical role in supplying oxygen (O₂) and nutrients to neuronal systems. An ischemic stroke typically presents with a rapid onset of neurological deficit. Cell–cell communication in the neurovascular unit contributes to a functional neurovascular system through an orchestrated network of extracellular matrix, endothelial cells (ECs), pericytes, astrocytes, oligodendrocytes, microglia, neural stem cells, and neurons. Thus, interruption of blood flow through an intracranial artery leads to deprivation of O₂ and nutrients to the vascular territory, resulting in metabolic changes in the surrounding cells, such as abnormal mitochondrial activity, inflammation, disruption of the blood–brain barrier (BBB), and cell death. Functional recovery after an ischemic stroke may depend on the fate of the ischemic penumbra if the circulation is re-established in time. If not, at the onset of a stroke, the complex and dynamic association between the brain vasculature and neuronal system delays functional recovery.

Elucidating the mechanism of neurovascular repair is important to develop therapeutic strategies to attempt to reverse or minimize the effects and to prevent future infarcts. Clinical trials aiming to develop strategies for neuroprotection with respect to ischemic stroke have failed to demonstrate clinical efficacy, possibly due to limited regenerative capacity in the central nervous system (CNS) [1]. In this review, we specifically discuss...
the repair mechanisms related to neurovascular protection and regeneration through stem cell-mediated repair mechanisms and gaseous molecule-mediated regenerative signaling. Additionally, strategies for overcoming a stroke are also discussed, with a specific focus on cellular therapy and molecular mechanisms involving vascular endothelial growth factor (VEGF). The VEGF family includes VEGF-A, -B, -C, -D, -E, and placental growth factor, which bind in a distinct pattern to three structurally related receptor-type tyrosine kinases, namely, VEGF receptor 1 (VEGFR1), VEGFR2, and VEGFR3. VEGF-A is a major growth factor that binds to VEGFR1 and VEGFR2 but not to VEGFR3 [2]. In this review, we have focused on VEGF-A and refer to it as VEGF because VEGF acts on entire neurovascular cells such as endothelial cells, neurons, and glia [3–8]. All these mechanisms involving stem cells and gaseous molecules partly share common molecular pathways and signaling molecules such as VEGF and its related factors.

2. Mechanisms Associated with the Neurovascular Unit Underlying Acute and Chronic Stroke

2.1. Neurovascular Damage Due to Acute and Chronic Stroke

Ischemic stroke can be divided into acute or chronic based on the time from onset. Ischemic stroke is classified as hyperacute, acute, subacute, and chronic with an onset time of 0–24 h, 1–7 days, and 1–3 weeks, respectively. ECs play key roles in neuroprotection by maintaining the integrity of the BBB during a stroke [9]. ECs in the CNS possess tight junctions (occludin, claudin, zonula occludens-1 (ZO-1), ZO-2, and ZO-3) and adherence junctions (VE-cadherin), which are reliant on several interdependent mechanisms (ionic dysregulation, inflammation, oxidative and nitrosative stress, enzymatic activity, and angiogenesis) for their functions [10]. In the neurovascular unit, surrounding cells, such as astrocytes and pericytes, contribute to the formation and maintenance of the BBB [11,12] by downregulating the expression of vascular permeability factors such as VEGF [13,14].

Strbian D. et al. demonstrated monophasic BBB leakage, starting as early as 25 min (acute phase) after post-ischemic reperfusion, and lasting for 3 weeks (chronic phase) detected by Evans blue staining [15]. In stroke patients, VEGF levels are increased in the neurons, astrocytes, and ECs of the ischemic penumbra [16]. In the acute phase of a stroke, excessive VEGF acts as a potent permeability factor [17,18]; however, in the chronic phase of ischemic injuries, administration of VEGF may strongly induce regenerative signaling, thereby mediating angiogenesis, neurogenesis, and synaptic function [4–6,19–22]. Thus, we discuss the neurovascular functions after a stroke focusing on cellular and molecular mechanisms associated with VEGF-mediated dual functions during the acute and chronic phases of a stroke.

2.1.1. Neurovascular Damage within Hours

A stroke directly damages the neural tissue and induces tissue ischemia attributed to vascular occlusion. During an acute stroke, ischemia/reperfusion leads to the disruption of BBB, loss of pericytes, activation of glia, macrophage infiltration, immune activation, inflammation, and neuronal cell death [10,23]. Pericyte constriction due to oxidative–nitrative stress has been observed 2 h after ischemia–reperfusion in the mouse brain [24]. Pericyte contraction entraps erythrocytes at the capillary constriction sites during a stroke, thereby obstructing microcirculation [24,25]. Occlusion of the cerebral artery leads to focal ischemia and upregulation of VEGF expression as early as 2–6 h after vessel occlusion [26,27]. VEGF levels are normalized within 12 h, are increased again following 3–7 days after reperfusion, and subsequently restored to baseline levels after 2 weeks [28]. Excessive VEGF levels demonstrate deleterious consequences such as BBB breakdown, vascular leakage, and brain edema [14,18]. Activation of VEGF/VEGFR2 signaling throughout stroke progression results in harmful effects during the acute phase of ischemia–reperfusion. The binding of VEGF to VEGFR2 stimulates vascular leakage through downstream signaling pathways, including the phosphoinositool-3-kinase (PI3K)-protein kinase B (PKB; Akt)-endothelial
nitric oxide synthase (eNOS) axis in ECs [29]. Hypoxic astrocyte-derived VEGF binds to VEGFR2 expressed on human retina microvascular ECs, leading to HIF-1α gene expression and consequent VEGF upregulation [30]. Inhibition of VEGFR2 signaling in ischemic stroke has been linked to a reduction in edema and infarct volume [31,32].

Impaired NO-mediated vascular functions are observed when NO reacts with reactive oxygen species (ROS) in the core region of the damaged brain. These effects can be mitigated by superoxide dismutase [33]. NADPH oxidase 2 (Nox2) may be the source of ROS since Nox2-deficient mice fail to demonstrate vascular tone after ischemia [33]. Reactive nitrogen species (RNS)-mediated structural alterations of vascular endothelial cadherin (VE-cadherin), attributed to nitrosylation of serine residues on VE-cadherin in ECs, are regarded as the mechanisms underlying early leakage in BBB [34]. In addition, the Src–Rac1–PAK (p21-activated kinase) pathway phosphorylates VE-cadherin, followed by its dissociation [35]. Furthermore, ischemic neurons facilitate astrocyte-derived VEGF production, leading to BBB breakdown via a reduction in the levels of tight junction proteins (occludin and claudin-5) [22] (Figure 1).

**Figure 1.** Following an acute ischemic stroke, VEGF, whose expression is enhanced, binds with VEGFR2 and triggers various signaling pathways in endothelial cells. For instance, the VEGFR2–PKC pathway may activate the transcription factor of VEGF and HIF-1α. Next, the PI3K–Akt pathway phosphorylates eNOS and activates eNOS enzymatic functions leading to NO production. Oxidative stress mediates ROS production. ROS reacts with NO to synthesize peroxynitrite (ONOOC−). ROS signaling inhibits PHD2 activity, leading to HIF-1α protein stabilization and activation of NF-κB protein, consequently upregulating expression of downstream genes related to NF-κB, such as IL-1β, TNF-α, IL-6, ICAM-1, and VCAM-1. ONOO− modifies VE-cadherin protein by nitrosylation of serine residues, resulting in the detachment of VE-cadherin from endothelial cells. Finally, the VEGFR2-mediated Src–Rac1–PAK pathway phosphorylates VE-cadherin, resulting in dissociation with the adherence junction between endothelial cells. Oxidative stress-mediated reduction in the expression of tight junction proteins also initiates BBB breakdown and monocyte infiltration. HIF-1α and NF-κB-mediated gene expression facilitates BBB breakdown, inflammatory responses, and glial scarring. Abbreviations: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; HIF-1α, hypoxia-induced factor-1α; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; PAK, p21-activated kinase; IL, interleukin; TNF-α, tumor necrosis factor α; VE-cadherin, vascular endothelial cadherin; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; ZO, zonula occludens; ROS, reactive oxygen species; PHD, prolyl-4-hydroxylase domain; BBB, blood–brain barrier.
Additionally, astrocyte and microglial activation may occur immediately after a stroke, amplified by multiple inflammatory factors, including tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-6, and adenosine triphosphate (ATP) [36,37]. These molecules act on a variety of recognition receptors expressed by microglia, astrocytes, oligodendrocytes, and oligodendrocyte precursor cells (OPCs) and trigger the activation of these cells [38,39]. Morphological changes in glial cells have been detected at varying distances and depths from the ischemic lesions in the ischemic brain [37,40].

2.1.2. Neurovascular Damage within Days

Following 1–2 days after injury, weakened tight junctions attract the infiltration of immune cells into ischemic brain tissues. Peripheral monocytes attach to the damaged brain ECs expressing intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which are the downstream factors of the kappa-light-chain-enhancer of activated B cells (NF-κB) observed during acute CNS inflammation [41] (Figure 1).

Inflammatory conditions lead to the downregulation of eNOS expression in ECs [42]. eNOS-derived NO possesses vasodilatory and anti-inflammatory properties as well as stroke-protective properties [43]. Neutrophils and other monocytes rapidly infiltrate the brain tissue and release additional pro-inflammatory cytokines that elicit a more robust reactive glial response and reinforce local inflammation [44]. In the ischemic core, round and amoeboid microglia can be observed at 1–3 days after a stroke. This effect stems from the changes in the morphology and polarization of microglia [40]. Some reactive astrocytes rapidly proliferate and densely populate the area around the lesion core within the 7–10-day period of glial scar formation [45,46]. Glial scars inhibit excessive inflammatory responses and restrict cellular degeneration [47].

The beneficial effects of VEGF in the subchronic phase of ischemia–reperfusion include tissue oxygenation via promotion of vasodilation, arteriogenesis in the penumbra area, angiogenesis, mitochondrial biogenesis, and neurogenesis [19,20,26,48]. VEGF improves neurological recovery after 48 h but not 1 h after ischemia [18]. In a rat model of transient focal ischemia induced by middle cerebral artery occlusion (MCAO), VEGF (1–3 days after ischemia) exerts multiple effects, such as neuroprotection, neurogenesis in the dentate gyrus and the subventricular zone, and angiogenesis in the striatal ischemic penumbra [48]. The in vivo ischemic brain injury model exhibited enhanced HIF-1α immunoreactivity in the peri-infarct region of the wild-type mice, which was abolished in heme oxygenase (HO)-1−/− heterozygote knockout (KO) mice [49]. HO-1-derived carbon monoxide (CO) stabilized HIF-1α via inactivation of prolyl-4-hydroxylase domain 2 (PHD2) due to O2 depletion, and HIF-1α induced ERRα expression [49]. PHD2 deficiency in neurons stabilizes HIF-1α protein and consequent VEGF mRNA levels not only in the neurons but also in astrocytes, demonstrating neuron-to-astrocyte signaling and pro-angiogenic responses [50].

Neural stem cells (NSCs) are self-renewing cells that can generate neurons, astrocytes, and oligodendrocytes. VEGF-overexpressing transgenic mice exhibited enhanced NSC proliferation, migration, and survival in the MCAO model [21]. As VEGF does not cross the BBB, circulating VEGF may activate neurogenesis indirectly in the CNS by upregulating the expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) in ECs [51,52].

2.1.3. Neurovascular Damage within Weeks

Immune-mediated inflammatory responses gradually cease within weeks after the injury, followed by endogenous repair. Upon endogenous angiogenesis and neurogenesis, increased cerebral blood flow (CBF) and maturation of ECs (tight junction integrity and interaction with pericytes) contribute, in part, to functional neural circuits.

In this phase, the glial scar matures completely partly via the signal transducer and activator of the transcription 3 (STAT3)-dependent mechanism [45]. In the STAT3-KO mice, the elongated processes of scar-forming astrocytes remain perpendicular to the lesion core and do not turn parallel to form a dense astrocytic scar border after CNS injury [45].
Astrocytes within the glial scar produce molecules that inhibit axonal growth. Semaphorin 3A, several ephrins, slits, and matrix components inhibit axon growth within the glial scar [46]. However, recent studies suggest that glial scarring stimulates regeneration [53]. STAT3 binds to the VEGF promoter, improves VEGF mRNA and protein expression, and enhances angiogenesis after a stroke [54]. In ischemic white matter injury, STAT3 is also involved in inducing morphological changes in the microglia (demonstrating an anti-inflammatory phenotype) mediated by the immune modulator, fingolimod [55].

In the next section, we will discuss regeneration mechanisms in the neurovascular unit after a stroke, specifically with respect to angiogenesis, gliogenesis, neurogenesis, and synaptogenesis.

2.2. Regeneration

In humans, functional repair following a severe stroke is very difficult [56]. Researchers have attempted to decipher the precise cellular and molecular mechanisms to overcome the limited ability of neurovascular recovery leading to normal brain functions after a stroke [1,57]. One critical aspect associated with the poor regeneration of central axons and glia is the inability of the environment to support axonal growth and myelination [57]. The neurovascular network may amplify the repair signals, and then support axonal regrowth by enhancing endogenous angiogenesis, gliogenesis, neurogenesis, and new synapse connections [58]. In this section, we discuss VEGF-mediated signaling pathways with respect to neurovascular components, such as neurons, NSCs, ECs, pericytes, astrocytes, microglia, and oligodendrocytes.

2.2.1. Neurons/NSCs

Accumulating evidence indicates that the VEGF–VEGFR2 axis mediates key neurobiological processes involved in neurogenesis, hippocampal plasticity, learning, and memory [3,20]. Co-activation of the NMDA receptor (NMDAR) and VEGFR2 in hippocampal pyramidal neurons triggers synaptogenesis and promotes synaptic targeting of NMDAR and VEGFR2 [4]. Overexpression of VEGF in vivo by intracerebral administration, gene transfer, or in conditional transgenic animal models demonstrates a VEGFR2-mediated increase in adult neurogenesis and improves hippocampal-dependent cognition [59]. Moreover, VEGFR2 is required for the beneficial effects of anti-depressant therapies on fear-related behavior [4]. In contrast, the depletion of endogenous VEGF via small hairpin RNA silencing or inducible expression of a VEGF trap leads to altered hippocampal neurogenesis in response to an enriched environment [3,6] or selective deficits in memory [59]. Both VEGF and VEGFR2 are expressed in the pyramidal cell layer and proximal apical dendrites in the cornu ammonis 1 (CA1) and CA3 regions of the hippocampi in postnatal day 15 mice [4], indicating that hippocampal pyramidal cells can respond to endogenous VEGF. Treatment with an inhibitor that specifically inhibits the tyrosine kinase activity of VEGFR2 diminishes the amplifying effect of VEGF [4]. NSCs, genetically modified by deleting the VEGFR2 gene, inhibits synaptogenesis, which is identified by detecting the expression of the presynaptic vesicle marker synapsin-1 and/or the postsynaptic density protein-95 [4]. Conditional KO of VEGFR2 via the Nestin-Cre system triggers selective VEGFR2 deletion in neural cells. Hippocampal neurons exhibit increased NMDA-type glutamate receptor (GluNRs)-mediated synaptic responses when VEGF is administered, whereas VEGF fails to induce any significant change in GluNR excitatory postsynaptic currents in VEGFR2 conditional KO slices [4]. Therefore, NSC-derived VEGF–VEGF signaling may trigger regeneration processes such as neurogenesis and synaptogenesis, leading to enhanced long-term memory.

2.2.2. Endothelial Cells (ECs)

Endogenous VEGF produced by ECs is crucial for vascular homeostasis [60]. Specific deletion of VEGF in ECs using VE-cadherin-driven Cre recombinase showed signs of severe failure of the cardiovascular system such as hemorrhages, microinfarcts, EC rupture,
and vascular constriction [60]. In this study, exogenous VEGF was unable to compensate for the loss of endogenous VEGF in ECs despite the fact that signaling through VEGFR2 activates several downstream pathways, including the PI3K–Akt pathway, which is responsible for cell survival. Micro-hemorrhages observed in VEGF-deficient ECs in adult mice (VEGF<sup>ECKO</sup>) are likely a reflection of the focal disruption of the vasculature attributed to EC death, as observed in vitro [61]. Additionally, the sudden death of a significant number of mutant VEGF<sup>ECKO</sup> mice was also observed [61]. In human umbilical vein ECs (HUVECs), the inactivation of VEGF results in mitochondrial fragmentation (as revealed by Hsp60 immunocytochemistry), the suppression of cell metabolism, and autophagic cell death [5]. These cellular phenotypes are mediated by forkhead box protein O1 (FOXO1), which is robustly stabilized in the absence of VEGF. When FOXO1 is deleted from VEGF-deficient endothelium, autophagic cell death is rescued, suggesting that the main role of autocrine VEGF is to regulate FOXO1 levels to maintain cellular homeostasis [5]. Therefore, the maintenance of baseline levels of VEGF in the endothelium is required to support vascular homeostasis.

Activation of VEGFR2 in ECs via binding with a strong agonist, VEGF, results in Akt-dependent phosphorylation of eNOS as well as NO production [62] (Figure 1). Increased CBF attributed to the VEGF–eNOS-NO pathway may facilitate ischemic tissue repair after a stroke [43]. Intravenous treatment with the eNOS substrate l-arginine mediated the blood-flow-dependent recovery in a rat model of an experimental stroke [63]. NO can increase the number of circulating endothelial progenitor cells (EPCs) after a stroke, consequently triggering neovascularization [64,65]. Treatment of human microvascular ECs with recombinant VEGF increases protein kinase C-mediated HIF-1α gene expression, leading to increased expression of downstream target genes such as glucose transporter-1 and VEGF [30]. Therefore, secreted VEGF influences vascular tone, angiogenesis, and glucose transport in the vascular system (Figure 1).

2.2.3. Astrocytes

Neuronal survival relies in part on astrocytic antioxidant abilities [66–68]. Following a stroke, ischemic tissues demonstrate O<sub>2</sub> and energy depletion, and subsequently, acidosis, inflammation, glutamate excitotoxicity, and ROS/RNS generation [69]. Oxidative stress leads to the fragmentation and autophagic degradation of mitochondria through excessive Ca<sup>2+</sup> influx in rat astrocytes [70]. Transfer of mitochondria from healthy astrocytes to adjacent ischemic-damaged neurons enhances neuronal survival and improves functional behavioral outcomes [71].

In astrocytes, Ca<sup>2+</sup> signaling stabilizes the hypoxia-inducible factor-1α (HIF-1α), thereby inducing the expression and secretion of VEGF [19,49]. Upon CNS injury, HIF-1α, a major transcription factor for VEGF, may trigger regenerative signaling pathways by manipulating various transcription factors [72,73]. The HO-1-CO pathway-mediated entry of extracellular Ca<sup>2+</sup> occurs through L-type voltage-gated Ca<sup>2+</sup> channels (VGCCs) [19]. Ca<sup>2+</sup> influx into astrocytes activates calmodulin-dependent protein kinase ββ (CaMKKββ)-mediated expression of AMP-activated protein kinase α (AMPKα) by enhancing phosphorylation and nicotinamide phosphoribosyltransferase (NAMPT)-mediated sirtuin 1 (SIRT1) activation. Subsequently, the peroxisome proliferator-activated receptor γ-coactivator-1α (PGC-1α)-estrogen-related receptor α (ERRα) axis is activated. These events result in up-regulated VEGF expression and secretion [19]. The L-type VGCC-mediated PGC-1α-ERR<sup>α</sup> axis strongly induces human astrocytic mitochondrial biogenesis [74]. Consequently, an increase in O<sub>2</sub> consumption stabilizes HIF-1α, leading to VEGF secretion and ERRα expression [49,75]. ERRα, a transcription factor for VEGF, also binds to HIF-1α and PGC-1α, leading to enhanced VEGF transcription [19,49]. Taken together, L-type VGCCs in human astrocytes may be involved in angiogenesis and mitochondrial biogenesis (Figure 2).

In primary rat cortical astrocytes with reduced O<sub>2</sub> availability (hypoxia and anoxia), the inhibition of protein kinase A reduced the expression of HIF-1α and phosphorylation of the cyclic AMP-responsive element-binding protein (CREB) and induced cell death [76].
Astrocyte-derived VEGF also activates the eNOS–NO pathway [77], possibly leading to the regulation of the vascular tone in ECs [78] (Figure 2).

Figure 2. After the ischemia-reperfusion injury, HO-1 is expressed in the astrocytes of the penumbra of the ischemic brain. CO and bilirubin can be produced via enzymatic activity of HO-1, which then activates the L-type Ca$^{2+}$ channel, leading to the entry of extracellular Ca$^{2+}$. Ca$^{2+}$-mediated AMPKα-ERRα axis induces mitochondrial biogenesis, ATP production, and increased O$_2$ consumption. Reduction of O$_2$ inhibits PHD2 activity and then stabilizes HIF-1α protein. Both the PGC-1α-ERRα pathway and HIF-1α pathway induce the expression and secretion of VEGF. VEGF dimerization and binding to VEGFR2 triggers the eNOS–NO axis and HIF-1α–VEGF pathway in endothelial cells, leading to vasodilation and angiogenesis, respectively. Abbreviations: CO, carbon monoxide; HO-1, heme oxygenase-1; AMPKα, AMP-activated protein kinase α; PGC-1α, peroxisome proliferator-activated receptor γ-coactivator-1α; PHD, prolyl-4-hydroxylase domain; ERRα, estrogen-related receptor α; SIRT1, sirtuin 1; NAMPT, nicotinamide phosphoribosyltransferase.

2.2.4. Pericytes

As pericytes are crucial for the maintenance of BBB integrity, they can also affect stroke progression and recovery. Brain pericytes are derived from neural crest cells and demonstrate various functions, including CBF regulation and BBB maintenance by communicating with other cells, especially ECs and astrocytes. The ratio of brain pericytes to ECs can range from 1:1 to 3:1 (endothelial-to-pericyte) [79,80]. Pericyte–EC interactions are prominent for BBB maintenance with profound effects on the basement membrane and endothelial tight junction architecture and function. During a stroke, pericyte detachment from ECs and pericyte death can influence BBB permeability [81]. The contractile properties of pericytes provide the capacity to regulate capillary blood flow. However, this may exert detrimental effects on oxidative–nitritative stress [24]. ATP and noradrenaline induce capillary constriction mediated by pericytes [82]. Glutamate reverses noradrenaline-induced constriction via prostaglandin E$_2$ and NO [25,82].
Platelet-derived growth factor (PDGF), VEGF, transforming growth factor-β, angiopoietin-1, and Wnt pathways play critical roles in EC–pericyte interaction [80]. Pericyte-derived angiopoietin-1 upregulates the expression of tight junction proteins in endothelial cells via the Tie-2 receptor [83]. EC-derived PDGF attracts pericytes. In addition, pericyte-derived angiopoietin-1 attracts Tie-2 receptor-expressing ECs [84]. These interactions mediate pericyte attachment and coverage of newly formed blood vessels, resulting in the maintenance of vascular homeostasis and maturation. This interaction can be defective in strokes. Hence, the repair of the EC–pericyte interaction facilitates vascular maturation and BBB repair.

2.2.5. Microglia/Macrophage

Microglia are the source of the inflammatory cascade activated during a brain injury. Cytokines, including TNF-α, IL-1β, and IL-6, are produced in significant amounts by microglia in the brain after an experimental brain injury. The pro-inflammatory phenotype of microglia is associated with tissue destruction, whereas the anti-inflammatory phenotype of microglia facilitates repair and regeneration. Mesenchymal stem cell (MSC) therapy may improve outcomes of an ischemic stroke by inhibiting the activity of the proinflammatory phenotype of microglia and augmenting the activity of the anti-inflammatory phenotype of microglia [85].

Peripheral monocytes infiltrate the ischemic lesion for up to 7 days and then differentiate into macrophages [86]. Inducible NOS (iNOS), expressed in the microglia/macrophages, is detected up to 7 days after MCAO [87]. VEGF-expressing microglia/macrophages may play a role in regeneration through cell–cell interactions [44]. VEGFR1 tyrosine kinase domain-deficient mice are healthy, and angiogenesis is normal in the embryo [88]. In VEGFR1-deficient mice, VEGF-dependent the migration of macrophages is blocked [88], supporting the hypothesis that VEGFR1 also generates a positive signal that stimulates cell migration.

2.2.6. Oligodendrocytes

Pericytes and vascular cells facilitate the proliferation and maturation of OPCs into oligodendrocytes [89,90]. Cerebral ECs, neurons, and astrocytes secrete VEGF [13,91,92], followed by the VEGF-induced migration of OPCs. This effect can be blocked by the VEGFR2 antibody [8]. VEGF-mediated adhesion kinase activation and ROS generation may be important mechanisms involved in OPC migration [8]. Taken together, myelination after CNS injury can be facilitated by repaired cells in the neurovascular unit such as pericytes, ECs, neurons, and astrocytes.

3. Neurovascular Repair

Stem cell therapy using MSCs, endothelial progenitor cells (EPCs), and neural stem cells (NSCs) may contribute to stroke recovery as stem cells can secrete a variety of cytokines and growth factors related to angiogenesis, neurogenesis, and synaptogenesis (Figure 3) [93]. Gaseous molecules such as NO and CO also possess regenerative potential demonstrated by boosting stem cell-mediated repair or by stimulating additional regenerative pathways [58,94,95]. Both pathways share common molecular mechanisms associated with VEGF and its related factors (Figure 3).

3.1. Stem Cell Therapy

Progress in stem cell biology has significantly contributed to the development of strategies for the treatment of strokes in preclinical studies and has demonstrated clinical potential in stroke treatment. Stem cell therapy may be a promising strategy for the treatment of intractable neurological diseases in the future. Transplanted exogenous stem cell therapy for a brain ischemic stroke may contribute directly to neurovascular regeneration (by compensating for the loss of nerve tissue by the differentiation of nerve and glial cells) as well as indirectly (via secretion of angiogenic and neurogenic factors
from the penumbra brain regions). Here, we discuss MSCs, EPCs, and NSCs as potential therapeutic cell types that might be beneficial for the treatment of strokes.

**Figure 3.** In the later phase of an ischemic stroke, VEGF expression may facilitate tissue regeneration. Exogenous stem cells (i.e., MSCs, EPCs, and NSCs) and gaseous molecules (i.e., NO and CO) increase the expression of VEGF and its related factors, which are involved in angiogenesis, neurogenesis, and synaptogenesis. Additionally, these factors enhance the ability of endogenous NSCs to proliferate and differentiate into mature neurons, astrocytes, and oligodendrocytes. Collectively, regeneration through stem cells and gaseous molecules contributes to repair after an ischemic stroke. Abbreviations: MSCs, mesenchymal stem cells; NSCs, neural stem cells; EPCs, endothelial precursor cells; BDNF, brain-derived neurotrophic factor; IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; SDF, stromal cell-derived factor; CO, carbon monoxide; NO, nitric oxide.

### 3.1.1. Mesenchymal Stem Cells

MSCs can differentiate into chondrocytes, adipocytes, and osteoblasts, as well as transdifferentiate into ECs, glial cells, and neurons. Owing to their remarkable regeneration potential, MSCs are widely used in current medical research [96]. MSCs secrete a wide range of growth factors, cytokines, chemokines, and extracellular vesicles, thereby contributing to the repair process (i.e., angiogenesis, gliogenesis, and neurogenesis) after an ischemic stroke [97].

The therapeutic potential of MSCs has been demonstrated in ischemic animal models. Human MSCs have been shown to enhance stroke lesion recovery by mediating inflammation and tissue repair through the secretion of trophic factors. Human MSC transplantation into a rat focal ischemia model of transient cerebral artery occlusion revealed decreased accumulation of Iba-1-positive microglia and GFAP-positive astrocytes and the inhibition of pro-inflammatory gene expression in the core and ischemic border zone [87]. MSC therapy may improve outcomes of an ischemic stroke by inhibiting the activity of the proinflammatory phenotype of microglia [85]. Human umbilical cord blood-derived MSCs (intravenous injection, 0.25 million cells/animal and 1 million cells/animal) were injected into a rat ischemia–reperfusion stroke model, and experiments were conducted 7 days after reperfusion [98]. The treatment reduced the mRNA and protein levels of metalloproteinases (MMPs) (i.e., MMP-9 and MMP-12) [98].
Apart from the anti-inflammatory responses, MSCs stimulate the regenerative pathway. B10 human MSCs express cytokines and growth factors, including IL-5, fractalkine, insulin-like growth factor-1, glia-derived neurotrophic factor, and VEGF [87]. B10 transplantation also increases the expression of angiogenic factors, such as HIF-1α in the core and border zone of rat ischemic stroke brains [99], which can induce VEGF expression and new vessel formation [99,100]. Allogeneic adipose-derived MSC sheets demonstrated neurological improvement with angiogenesis and neurogenesis in a rat stroke model [101]. Mitochondrial transfer from MSCs to cerebral microvasculature resulted in significant improvement of the mitochondrial activity in injured microvasculature, enhanced angiogenesis, reduced infarct volume, and improved functional recovery following an ischemic stroke [102].

Stromal cell-derived factor-1α (SDF-1α)-transfected MSCs enhance ischemia-mediated new vessel formation as well as angiogenesis in vivo via the VEGF–eNOS axis [103]. IFN-γ-activated MSCs were injected into a rat MCAO model. IFN-γ-activated MSCs demonstrated more potent functional recovery as assessed by the modified neurological severity score and open-field analysis compared to that observed in vehicle-treated animals [104]. IFN-γ-activated MSC-treated stroke-conditioned animals showed a reduction in infarct size, diminished microglial activation, and enhanced recruitment and differentiation of OPCs to myelin-producing oligodendrocytes [104]. Intra-arterial transplantation of 3-dimension (3D) aggregate-derived human MSCs into transient MCAO stroke model mice exhibited increased cell persistence and better therapeutic outcomes compared to that in saline control or 2D human MSC control [105]. The PI3K–Akt signaling pathway was activated by 3D-aggregate-human MSCs [105]. The extracellular regulating kinase 1/2 (ERK) pathway is considered an important regulator in CNS regeneration [58,106]. ERK-overexpressing MSCs were transplanted into stroke model rats, demonstrating the increased proliferation of NSCs and maturation into neurons in the subventricular zone [107]. Glia-like human MSCs (ghMSCs) exhibit better efficacy and enable better protection of the neurons and the brain from ischemia than naïve human MSCs, and insulin-like growth factor binding protein-4 (IGFBP-4) played a critical role in mediating the beneficial effects of ghMSCs in an ischemic stroke [108]. IGFBP-4, hepatocyte growth factor, and VEGF released from ghMSCs may serve as key molecules for enhanced neuronal survival and neurite outgrowth in ischemic CNS injuries [108,109]. Small extracellular vesicles secreted by human-induced pluripotent stem cell-derived MSCs enhance angiogenesis by inhibiting STAT3-dependent autophagy in a rat model of an ischemic stroke [110]. MSC transplantation has also been investigated in humans. Autologous MSC transplantation (intravenous injection, 1 × 10^8 cells) may improve neurological functions one year after symptom onset in stroke patients [111]. In this study, of the 31 enrolled patients, 16 were administered MSCs. The MSC-treated group showed improvements in motor functioning based on the examination of the National Institutes of Health Stroke Scale score and Fugl-Meyer scores as well as in task-related functional magnetic resonance imaging activity [112]. The transplantation of autologous human MSCs (intravenous injection), cultured in human serum, was performed in 12 stroke patients [113]. In this unblinded study, the mean lesion volume, as assessed by magnetic resonance imaging, was reduced by 420% at one week post-cell infusion [113]. Allogeneic ischemia-tolerant MSCs (intravenous injection, 0.5, 1.0, and 1.5 million cells/kg body weight) were transfused into patients with chronic stroke. Their Barthel index scores increased at 6 months and 12 months post-infusion [114]. Taken together, MSCs may exhibit therapeutic potential by inhibiting excessive inflammation and stimulating the repair pathway.

3.1.2. Endothelial Progenitor Cells (EPCs)

The formation of new blood vessels in the adult brain after a stroke stems from angiogenesis (migration and proliferation of local mature ECs) and the systemic regulation of bone marrow-derived EPCs [93]. CD34 and VEGFR2 double-positive mononuclear cells from peripheral blood are considered as EPCs [115]. EPC mobilization from the bone
marrow stroma into the blood circulation is regulated by various enzymes and factors such as eNOS, VEGF, and granulocyte colony-stimulating factor (G-CSF) [43,116,117]. The SDF-1α/C-X-C motif chemokine receptor 4 (CXCR4) pathway plays a key role in the homing of EPCs to the ischemic region [93,118]. The SDF-1α–CXCR4 interaction may recruit not only EPCs, but also MSCs and NSCs to ischemic tissues since the SDF-1–CXCR4 axis modulates survival, proliferation, migration, and differentiation of MSCs and NSCs [119,120].

Ex vivo expanded EPCs (intravenous injection, $1 \times 10^6$ cells) were injected into mice after 1 h following induction of transient MCAO [121]. EPC transplantation significantly reduced ischemic infarct volume and induced angiogenesis in the ischemic penumbra after MCAO compared to that observed in control mice in vivo, and a CXCR4 antagonist blocked SDF-1-mediated EPC migration in vitro [121]. Moreover, SDF-1 upregulates VEGF expression and eNOS activity via cellular communication [103].

The interplay between eNOS and BDNF may be involved in EPC-mediated angiogenesis, neurogenesis, and axonal growth after an ischemic stroke [122]. Conditioned media derived from EPC culture was administered to mice 1 d after MCAO. A significant increase in capillary density was observed in the ischemic penumbra, consequently improving forelimb strength [123]. The expression of multiple growth factors, cytokines, and proteases has been demonstrated in the EPC secretome, showing enhanced endothelial and OPC proliferation and maturation [90]. Angiogenin, a HIF-1α target gene, may be a key factor since pharmacological blockade of angiogenin signaling negates the positive effects of the EPC secretome [90,124]. Under in vivo conditions, treatment with the EPC secretome increases vascular density, myelin, and mature oligodendrocytes in the white matter and rescues cognitive function in a mouse model of hypoperfusion [90]. Hypoxic preconditioning via overexpression of HIF-1α, SDF-1α, VEGFR2, or VEGF may facilitate EPC functions such as angiogenesis and neurogenesis [125,126].

Autologous CD34-positive stem/progenitor cells derived from the bone marrow of human subjects were administered intra-arterially via catheter angiography within 7 days of the onset of a severe ischemic stroke [127]. In this study, administration of CD34-positive stem cells resulted in reduced lesion volume and hence, rescued patients with an acute ischemic stroke during a 6-month follow-up period [127]. Thus, the application of EPCs in an ischemic stroke may be helpful.

### 3.1.3. Neural Stem Cells (NSCs)

IL-17A shows two distinct peaks of expression in the ischemic hemisphere: the first peak observed after 3 days and the second on day 28 after a stroke. Astrocytes are a major cellular source of IL-17A, which maintains and augments subventricular zone (SVZ) neuronal precursor cell survival, neuronal differentiation, synaptogenesis, and functional recovery after a stroke [128]. In this study, the p38 mitogen-activated protein kinase–calpain 1 signaling pathway was involved in IL-17A-mediated neurogenesis [128].

NAMPT is a rate-limiting enzyme involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD) in mammals; this putative therapeutic agent for combating stroke is highly expressed in neurons, EPCs, and NSCs, with lower expression in glial cells [129,130]. It plays key roles in defense mechanisms, metabolic homeostasis, and neuronal survival [129]. NAD replenishment in neurons either before or after oxygen-glucose deprivation reduces cell death and DNA damage [131]. Neuronal survival due to NAMPT overexpression was blocked in AMPKα2−/− neurons through the SIRT1–AMPK axis in a rat model of an ischemic stroke [132]. The role of NAMPT has been demonstrated in neurovascular repair during the chronic phase. NAMPT promotes angiogenesis, neovascularization, and neurite outgrowth as well as increases the levels of regenerative factors such as BDNF and VEGF [129,133–135].

### 3.2. Gaseous Biomolecules

Reduced $O_2$ availability (i.e., hypoxia) and energy substrates (e.g., glucose) appear to represent the critical stimulus that evokes an adaptive response to ischemia, principally
through HIF-dependent production of multiple angiogenic cytokines and growth factors, including VEGF, angiogenin, angiopoietins, placental growth factor, PDGF-B, stem cell factor, and SDF-1, which stimulate angiogenesis, the process of new blood vessel formation from pre-existing ones [27,124,136–139].

The endogenous repair ability of gaseous biomolecules such as NO and CO can be promoted after a stroke. Nitric oxide (NO) and CO are endogenous gases produced by NOS and HO, which diffuse freely between cells, consequently amplifying signaling pathways involved in neurogenic and angiogenic functions [42,137]. NO can dilute the cerebral vasculature and enhance cerebral blood flow. CO improves damaged vasculature by inducing angiogenesis and neovascularization, partly by interacting with the NOS signaling pathway [94]. Moderate levels of NO and CO induces HIF-1α-mediated VEGF expression [75,140] and suppress its expression in severe hypoxia [141].

3.2.1. NO

NO is produced by the reaction of l-arginine with NOS isoforms. Two constitutive isoforms, (eNOS and neuronal NOS [nNOS]) via Ca\(^{2+}\) entry, and iNOS are enzymes that are expressed in a highly cell type-specific manner. Acting as an intercellular signal, the nNOS–NO axis can trigger neurogenesis in mouse brain neural progenitor cells. BDNF upregulates nNOS protein levels, which can induce the maturation of neurons from neural progenitor cells [142].

VEGF–VEGFR2–PI3K–Akt axis is an important regulator of cellular survival, cell motility, and NO production [143,144]. Activation of AMPK, a crucial cellular energy sensor, can also stimulate eNOS by phosphorylating it at Ser\(^{1179}\), suggesting crosstalk between cellular metabolism and vascular tone. By using flow channels with cultured ECs, AMPK\(^{\alpha}\)Thr\(^{172}\) phosphorylation can be increased with changes in flow rate or pulsatility [145].

eNOS exhibits neuroprotective properties against ischemic strokes [43]. Moderate NO gas inhalation in mice with transient focal ischemia reduced infarct volume to 10 ppm for 24 h, and to 20, 40, and 60 ppm for 8 and 16 h following NO inhalation [146]. NO inhalation improves penumbral blood flow and neurological outcomes in a mice ischemia induced by transient MCAO [147] and in a rat model of focal cerebral ischemia [63].

An HO inducer or carbon monoxide-releasing molecule 2 (CORM-2) restores TNF-α-induced downregulation of the expression of eNOS–NO by inhibiting NF-κB-responsive miR-155-5p expression in HUVECs [42]. CO can reduce the production of ROS, consequently reducing the synthesis of peroxynitrite [148]. Application of CORM-2 in BV2 microglial cells prevents the production of NO upon lipopolysaccharide (LPS) stimulation [149]. Therefore, CO may reduce LPS-mediated NO production in activated glial cells and stimulate NO production in vascular cells. In addition, CO may facilitate repair and regeneration by activating the nNOS–NO pathway in neuronal cells [95]. The interplay between CO and NO leads to vascular dilation, angiogenesis, and neurogenesis.

The nNOS–NO axis is activated in the neurons and NSCs when mice are injected with CORM-3 after an ischemic CNS injury [95]. CO may exert neurogenic effects by stimulating the HO-1 pathway, consequently activating the nNOS–NO axis. The HO metabolite, bilirubin, stimulates ERK1/2 phosphorylation, CREB phosphorylation, and nNOS–NO production in the absence of exogenous growth factors in PC12 cells. This effect is blocked by an extracellular Ca\(^{2+}\) chelator [150]. NMDAR, a critical receptor for hippocampal long-term potentiation and spatial learning, is S-nitrosylated by NO [150]. Thus, the crosstalk between HO/CO and NOS/NO may induce diverse signaling pathways leading to neurogenesis, long-term potentiation, learning, and memory.

3.2.2. Carbon Monoxide (CO)

HO-1 and HO-2 are essential enzymes in heme catabolism that cleave heme to carbon monoxide (CO), biliverdin (which is rapidly converted to bilirubin), and Fe\(^{2+}\). In this step, O\(_2\) is required as the reaction substrate [136]. HO-2 is constitutively expressed in neurons where it functions as an intrinsic protector [151]. The expression of HO-1 is strongly
induced in various cells in response to hypoxia and stress, which promotes neuroprotection and angiogenesis in the ischemic milieu [152]. CO induces the expression of HO-1 and plays important roles in neurotransmission, neurogenesis, mitochondrial biogenesis, and blood circulation in the brain [153–155]. CO generated either by exogenous delivery or by HO activity is fundamentally involved in regulating mitochondria-mediated redox cascades for adaptive gene expression and improving blood circulation (i.e., O$_2$ delivery) via neovascularization, leading to the regulation of mitochondrial energy metabolism [137]. CO can be delivered in a pharmacologically active form as a CO-releasing molecule, CORM [156]. The biological effects of CO are largely dependent on the HO activity [137].

HO-derived CO promotes angiogenesis and neovascularization by regulating pro-angiogenic VEGF expression [157–160]. CO can also upregulate HO-1 expression, and the HO-1/CO circuit may interact with the NOS/NO pathway [94]. CORM-2 can stimulate the eNOS–NO axis through inositol triphosphate receptor-mediated intracellular Ca$^{2+}$ release, PI3K-Akt phosphorylation, and eNOS dimerization in HUVECs [161]. CORM-2 prevents TNF-$\alpha$-induced eNOS downregulation by inhibiting NF-$\kappa$B-responsive miR-155-5p biogenesis [42]. Inflammatory responses after ischemic stroke are diminished by CORM-3, demonstrated by examining the levels of TNF-$\alpha$ and IL-1$\beta$ [162]. CO-mediated ROS/RNS inhibition may protect the BBB from acute neuroinflammatory diseases [95,162].

Signaling pathways activated by CORM-2 include the PI3K-HIF-1$\alpha$–VEGF pathway [75]. In a mouse model of ischemia–reperfusion injury, HO-1 is expressed in astrocytes in the penumbra region [19]. Transient HO-1 activation may be beneficial for regeneration during an acute ischemic injury [95,156,163–166]. HO-1-derived CO and bilirubin activate LTCC and mediate Ca$^{2+}$/CaMKK$\beta$-mediated activation of AMPK$\alpha$, AMPK$\alpha$-dependent HO-1 induction, and the consequent stabilization of HIF-1$\alpha$ in a PHD2-dependent manner [49]. The effects of CO on regeneration are associated with VEGF production [19]. Recently, the neuroprotective and regenerative effects of CORM-3 have been demonstrated in a stroke. CORM-3 injection reduced infarct volume and increased the expression of mature neuronal markers such as neuronal nuclear antigen and microtubule-associated protein 2 compared to that in saline-treated mice [162]. CO-mediated VEGF upregulation does not disrupt BBB, instead, CO protects the BBB from ischemic injury [95,162]. CO-mediated protective factors may mitigate VEGF-mediated vascular permeability, or CO reduces excessive VEGF production. Taken together, CO reduces VEGF-mediated disruption of BBB and facilitates VEGF-induced regeneration after an ischemic stroke.

4. Discussions/Conclusions

The present review discusses the repair potential of various exogenous stem cells and gaseous molecules with respect to neurovascular protection and regeneration after an ischemic stroke. Ischemic stroke is a complex disease with multiple underlying pathways. To address this multiplicity, therapeutic agents may target more than one pathway, such as anti-inflammation, neuroprotection, and neurovascular regeneration involved in angiogenesis, neurogenesis, and gliogenesis. Commonly shared key molecular mechanisms in the neurovascular unit repair are associated with the VEGF and its related factors.

A neurotrophic supportive environment may contribute to neurovascular regeneration and the formation of functional neural circuits upon an ischemic stroke. Exogenous stem cells and gaseous molecules have been used to treat ischemic strokes. This strategy includes enhancing VEGF-mediated regeneration and the ability of VEGF-related factors to amplify the cellular network in the CNS. The crosstalk between cells and the regenerative ability of these cell-derived factors boosts renewal potential by activating the functions of endogenous NSCs (Figure 4).

Nevertheless, current studies examining the repair following an ischemic stroke have limited applicability for humans, possibly owing to the disconnection between animal models employed by the laboratory and actual disease states observed in humans [167,168]. In addition to developing proper animal models for representing an ischemic stroke, the administration of a single drug to ischemic stroke patients would not be sufficient to repair
the entire neurovascular unit. Therefore, the administration of a cocktail of therapeutic drugs, discussed in this review, with multiple regenerative mechanisms may be beneficial.

Figure 4. Neuronal growth-promoting environment supported by exogenous stem cells and gaseous molecules may contribute to repair upon ischemic stroke. Cellular and molecular crosstalk in the neurovascular unit leads to BBB maturation, angiogenesis, neurogenesis, gliogenesis, and synaptogenesis. Collectively, damaged tissue may be repaired through these regenerative pathways and form new functional neural circuits. Abbreviations: BBB, Blood–Brain Barrier; BDNF, brain-derived neurotrophic factor; EPCs, endothelial precursor cells; MSCs, mesenchymal stem cells; NAMPT, nicotinamide phosphoribosyltransferase; NSCs, neural stem cells; SDF-1, stromal cell-derived factor-1; VEGF, vascular endothelial growth factor.

Author Contributions: S.M., M.-S.C., S.-H.K. and Y.K.C. wrote the manuscript. Y.K.C. supervised this project. All authors have agreed to the published version of the manuscript.

Funding: This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI20C0255). This paper was supported by the National Research Foundation of Korea (NRF) grant (2020R1A2C1004397) funded by the Korean Government.

Acknowledgments: Y.K.C. is grateful to Y.-M.K. (Kangwon National University, Korea) for his useful discussions.

Conflicts of Interest: There are no conflict of interest.

References
1. Mahar, M.; Cavalli, V. Intrinsic mechanisms of neuronal axon regeneration. Nat. Rev. Neurosci. 2018, 19, 323–337. [CrossRef]
2. Shibuya, M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb. Perspect. Biol. 2013, 5, a009092. [CrossRef]
9. Seo, J.H.; Maki, T.; Miyamoto, N.; Choi, Y.K.; Chung, K.K.; Hamanaka, G.; Park, J.H.; Mandeville, E.T.; Takase, H.; Hayakawa, K.; During, M.J.; Cao, L. VEGF, a mediator of the effect of experience on hippocampal neurogenesis. *Curr. Alzheimer Res.* 2006, 3, 29–33. [CrossRef]

10. Eikelen, H.M.; Dieguez-Hurtado, R.; Schmidt, I.; Nakayama, M.; Jeong, H.W.; Arf, H.; Adams, S.; Ferrara, N.; Adams, R.H. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1. *Nat. Commun.* 2017, 8, 1574. [CrossRef]

11. Hayakawa, K.; Pham, L.D.; Som, A.T.; Lee, B.J.; Guo, S.; Lo, E.H.; Ariai, K. Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. *J. Neurosci.* 2011, 31, 10666–10670. [CrossRef]

12. Seo, J.H.; Maki, T.; Miyamoto, N.; Choi, Y.K.; Chung, K.K.; Hamaanaka, G.; Park, J.H.; Mandeville, E.T.; Takase, H.; Hayakawa, K.; et al. AKAP12 Supports Blood-Brain Barrier Integrity against Ischemic Stroke. *Int. J. Mol. Sci.* 2020, 21, 78. [CrossRef]

13. Sandoval, K.E.; Witt, K.A. Blood-brain barrier tight junction permeability and ischemic stroke. *Neurobiol. Dis.* 2008, 32, 200–219. [CrossRef]

14. Strbian, D.; Durukan, A.; Pitkonen, M.; Marinkovic, I.; Tatlisumak, E.; Pedrono, E.; Abo-Ramadan, U.; Tatlisumak, T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. *Neuroscience* 2008, 153, 175–181. [CrossRef] [PubMed]

15. Issa, R.; Krupinski, J.; Buinjy, T.; Kumar, S.; Kaluza, J.; Kumar, P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. *Lab. Invest.* 1999, 79, 417–425. [CrossRef]

16. Pedram, A.; Razandi, M.; Levin, E.R. Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. *J. Biol. Chem.* 2002, 277, 44385–44398. [CrossRef] [PubMed]

17. Zhang, Z.G.; Zhang, L.; Jiang, Q.; Zhang, R.; Davies, K.; Powers, C.; Bruggen, N.; Chopp, M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the brain. *J. Clin. Investig.* 2000, 106, 829–838. [CrossRef] [PubMed]

18. Cho, Y.K.; Kim, J.H.; Lee, D.K.; Lee, K.S.; Won, M.H.; Jeong, D.; Lee, H.; Ha, K.S.; Kwon, Y.G.; Kim, Y.M. Carbon Monoxide Potentiation of L-Type Ca2+ Channel Activity Increases HIF-1alpha- Independent VEGF Expression via an AMPKalpha/SIRT1- Mediated PGC-1alpha/Alpapha. *Antioxid Redox Signal.* 2017, 27, 21–36. [CrossRef]

19. Jin, K.; Zhu, Y.; Sun, Y.; Mao, X.O.; Xie, L.; Greenberg, D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. *Proc. Natl. Acad. Sci. USA* 2002, 99, 11946–11950. [CrossRef] [PubMed]

20. Wang, Y.; Jin, K.; Mao, X.O.; Xie, L.; Banwart, S.; Marti, H.H.; Greenberg, D.A. VEGF-overexpressing transgenic mouse show enhanced post-ischemic neurogenesis and neourmigoration. *J. Neurosci.* 2007, 25, 740–747. [CrossRef]

21. Li, Y.N.; Pan, R.; Qin, J.X.; Yang, W.L.; Qi, Z.; Liu, W.; Liu, K.J. Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression. *J. Neurochem.* 2014, 129, 120–129. [CrossRef]

22. Jiang, X.; Andjelkovic, A.V.; Zhu, L.; Yang, T.; Bennett, M.V.L.; Chen, J.; Keep, R.F.; Shi, Y. Blood-brain barrier dysfunction and recovery after ischemic stroke. *Prog. Neurobiol.* 2018, 163–164, 144–171. [CrossRef] [PubMed]

23. Yemisci, M.; Gursoy-Ozdemir, Y.; Vural, A.; Can, A.; Topalkara, K.; Dalkara, T. Pericyte contact induced by oxidative-nitritive stress impairs capillary reflow despite successful opening of an occluded cerebral artery. *Nat. Med.* 2009, 15, 1031–1037. [CrossRef] [PubMed]

24. Hall, C.N.; Reynell, C.; Gesslein, B.; Hamilton, N.B.; Mishra, A.; Sutherland, B.A.; O’Farrell, F.M.; Buchan, A.M.; Lauritzen, M.; Attwell, D. Capillary pericytes regulate cerebral blood flow in health and disease. *Nature* 2014, 508, 55–60. [CrossRef]

25. Marti, H.J.; Bernaudin, M.; Bellail, A.; Schoch, H.; Euler, M.; Petit, E.; Risau, W. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. *Am. J. Pathol.* 2000, 156, 965–976. [CrossRef]

26. Zhang, Z.G.; Zhang, L.; Tsang, W.; Soltanian-Zadeh, H.; Morris, D.; Zhang, R.; Goussev, A.; Powers, C.; Yeich, T.; Chopp, M. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. *J. Cereb. Blood Flow Metab.* 2002, 22, 379–392. [CrossRef]

27. Zan, L.; Zhang, X.; Xi, Y.; Wu, H.; Song, Y.; Teng, G.; Li, H.; Qi, J.; Wang, J. Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion. *Neuroscience* 2014, 262, 118–128. [CrossRef]

28. Nilsson, M.; Heymach, J.V. Vascular endothelial growth factor (VEGF) pathway. *J. Thorac. Oncol.* 2006, 1, 768–770. [CrossRef]
30. Choi, Y.K. A positive circuit of VEGF increases Glut-1 expression by increasing HIF-1alpha gene expression in human retinal endothelial cells. *Arch. Pharm. Res.* **2017**, *40*, 1433–1442. [CrossRef]
31. Van Bruggen, N.; Thibodeaux, H.; Palmer, J.T.; Lee, W.P.; Fu, L.; Cairns, B.; Tumas, D.; Gerloi, R.; Williams, S.P.; van Lookeren Campagne, M.; et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. *J. Clin. Investig.* **1999**, *104*, 1613–1620. [CrossRef] [PubMed]
32. Kimura, R.; Nakase, H.; Tamaki, R.; Sakaki, T. Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction. *Stroke* **2005**, *36*, 1259–1263. [CrossRef] [PubMed]
33. De Silva, T.M.; Brair, V.H.; Drummond, G.R.; Sobey, C.G.; Miller, A.A. Nox2 oxidase activity accounts for the oxidative stress and vasomotor dysfunction in mouse cerebral arteries following ischemic stroke. *PLoS ONE* **2011**, *6*, e28393. [CrossRef]
34. Di Lorenzo, A.; Lin, M.I.; Murata, T.; Landskroner-Eiger, S.; Schleicher, M.; Kothiya, M.; Iwakiri, Y.; Yu, J.; Huang, P.L.; Sessa, W.C. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. *J. Cell Sci.* **2013**, *126*, 5541–5552. [CrossRef]
35. Gavard, J. Endothelial permeability and VE-cadherin: A wacky comradeship. *Cell Adhes. Migr.* **2014**, *8*, 158–164. [CrossRef] [PubMed]
36. Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Munch, A.E.; Chung, W.S.; Peterson, T.C.; et al. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* **2017**, *541*, 481–487. [CrossRef] [PubMed]
37. Liddelow, S.A.; Barres, B.A. Reactive Astrocytes: Production, Function, and Therapeutic Potential. *Immunity* **2017**, *46*, 957–967. [CrossRef] [PubMed]
38. Franke, H.; Grosche, J.; Schädlich, H.; Krugel, U.; Allgaier, C.; Illis, P. P2X receptor expression on astrocytes in the nucleus accumbens of rats. *Neuroscience* **2001**, *108*, 421–429. [CrossRef]
39. Badan, I.; Buchhold, B.; Ham, A.; Gratz, M.; Walker, L.C.; Platt, D.; Kessler, C.; Popa-Wagner, A. Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. *J. Cereb. Blood Flow Metab.* **2003**, *23*, 845–854. [CrossRef] [PubMed]
40. Heindl, S.; Gesierich, B.; Benakci, K.; Llovera, G.; Duerinck, M.; Liesz, A. Automated Morphological Analysis of Microglia After Stroke. *Front. Cell Neurosci.* **2018**, *12*, 106. [CrossRef]
41. Kim, J.H.; Kyung Choi, Y.; Lee, K.S.; Cho, D.H.; Baek, Y.Y.; Lee, D.K.; Ha, K.S.; Choe, J.; Won, M.H.; Jeoung, D.; et al. Functional dissection of Nr2f2-dependent phase II genes in vascular inflammation and endothelial toxicity using Keap1 siRNA. *Free Radic. Biol. Med.* **2012**, *52*, 629–640. [CrossRef] [PubMed]
42. Choi, S.; Kim, J.; Kim, J.H.; Lee, D.K.; Park, W.; Park, M.; Kim, S.; Hwang, J.Y.; Won, M.H.; Choi, Y.K.; et al. Carbon monoxide prevents TNF-alpha-induced eNOS downregulation by inhibiting NF-kappaB-responsive miR-155-5p biogenesis. *Exp. Mol. Med.* **2017**, *49*, e403. [CrossRef] [PubMed]
43. Endres, M.; Laufs, U.; Liao, J.K.; Moskowitz, M.A. Targeting eNOS for stroke protection. *Trends Neurosci.* **2004**, *27*, 283–289. [CrossRef]
44. Qin, C.; Zhou, L.Q.; Ma, X.T.; Hu, Z.W.; Yang, S.; Chen, M.; Bosco, D.B.; Wu, L.J.; Tian, D.S. Dual Functions of Microglia in Ischemic Stroke. *Neurosci. Bull.* **2013**, *29*, 11–24. [CrossRef] [PubMed]
45. Wanner, I.B.; Anderson, M.A.; Song, B.; Levine, J.; Fernandez, A.; Gray-Thompson, Z.; Ao, Y.; Sofroniew, M.V. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. *Cell Tissue Res.* **2018**, *371*, 629–640. [CrossRef] [PubMed]
46. Huang, L.; Wu, Z.B.; Zhuge, Q.; Zheng, W.; Shao, B.; Wang, B.; Sun, F.; Jin, K. Glial scar formation occurs in the human brain after ischemic stroke. *Int. J. Mol. Sci.* **2011**, *13*, 344–348. [CrossRef]
47. Silver, J.; Miller, J.H. Regeneration beyond the glial scar. *Nat. Rev. Neurosci.* **2004**, *5*, 146–156. [CrossRef]
48. Sun, Y.; Jin, K.; Xie, L.; Childs, J.; Mao, X.O.; Logvinova, A.; Greenberg, D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. *J. Clin. Investig.* **2003**, *111*, 1843–1851. [CrossRef] [PubMed]
49. Choi, Y.K.; Park, J.H.; Yun, J.A.; Cha, J.H.; Kim, Y.; Won, M.H.; Kim, K.W.; Ha, K.S.; Kwon, Y.G.; Kim, Y.M. Heme oxygenase metabolites improve astrocytic mitochondrial function via a Ca2+-dependent HIF-1alpha/ERRalpha circuit. *PLoS ONE* **2018**, *13*, e0202039. [CrossRef] [PubMed]
50. Nasyrov, E.; Nolan, K.A.; Wenger, R.H.; Marti, H.H.; Kunze, R. The neuronal oxygen-sensing pathway controls postnatal vascularization of the murine brain. *FASEB J.* **2019**, *33*, 12812–12824. [CrossRef] [PubMed]
51. Zaccomo, S.; Lambrechts, D.; Carmeliet, P. Neurovascular signalling defects in neurodegeneration. *Nat. Rev. Neurosci.* **2008**, *9*, 169–181. [CrossRef] [PubMed]
52. Louissaint, A., Jr.; Rao, S.; Leventhal, C.; Goldman, S.A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. *Neuron* **2002**, *34*, 945–960. [CrossRef] [PubMed]
53. Anderson, M.A.; Burda, J.E.; Ren, Y.; Ao, Y.; O’Shea, T.M.; Kawaguchi, R.; Coppola, G.; Khakh, B.S.; Deming, T.J.; Sofroniew, M.V. Astrocyte scar formation aids central nervous system axon regeneration. *Nature* **2016**, *532*, 195–200. [CrossRef] [PubMed]
54. Dong, W.; Xian, Y.; Yuan, W.; Huifeng, Z.; Tao, W.; Zhiquiang, L.; Shan, F.; Ya, F.; Hongli, W.; Jinghuan, W.; et al. Catalpol stimulates VEGF production via the JAK2/STAT3 pathway to improve angiogenesis in rats’ stroke model. *J. Ethnopharmacol.* **2016**, *179*, 169–179. [CrossRef] [PubMed]
55. Qin, C.; Fan, W.H.; Liu, Q.; Shang, K.; Murugan, M.; Wu, L.J.; Wang, W.; Tian, D.S. Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway. *Stroke* **2017**, *48*, 3336–3346. [CrossRef] [PubMed]
56. Schwab, M.E.; Strittmatter, S.M. Nogo limits neural plasticity and recovery from injury. *Curr. Opin. Neurobiol.* **2014**, *27*, 53–60. [CrossRef]
57. Tedeschi, A.; Bradke, F. Spatial and temporal arrangement of neuronal intrinsic and extrinsic mechanisms controlling axon regeneration. *Curr. Opin. Neurobiol.* **2017**, *42*, 118–127. [CrossRef]
58. Jung, E.; Koh, S.H.; Yoo, M.; Choi, Y.K. Regenerative Potential of Carbon Monoxide in Adult Neural Circuits of the Central Nervous System. *Int. J. Mol. Sci.* **2020**, *21*, 2273. [CrossRef]
59. Licht, T.; Goshen, I.; Avital, A.; Kreisel, T.; Zubedat, S.; Eavri, R.; Segal, M.; Yirmiya, R.; Keshet, E. Reversible modulations of neuronal plasticity by VEGF. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 5081–5086. [CrossRef]
60. Lee, S.; Chen, T.T.; Barber, C.L.; Jordan, M.C.; Murdock, J.; Desai, S.; Ferrara, N.; Nagy, A.; Roos, K.P.; Iruela-Arispe, M.L. Autocrine VEGF signaling is required for vascular homeostasis. *Cell* **2007**, *130*, 691–703. [CrossRef]
61. Domingues, I.; Rino, J.; Dömmers, J.A.; de Lanerolle, P.; Santos, S.C. VEGFR2 translocates to the nucleus to regulate its own transcription. *PLoS ONE* **2011**, *6*, e25668. [CrossRef]
62. Mistry, R.K.; Brewer, A.C. Redox regulation of gasotransmission in the vascular system: A focus on angiogenesis. *Free Radic. Biol. Med.* **2017**, *108*, 500–516. [CrossRef]
63. Dalkara, T.; Morikawa, E.; Panahian, N.; Moskowitz, M.A. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. *Am. J. Physiol.* **1994**, *267*, H678–H683. [CrossRef] [PubMed]
64. Murohara, T.; Asahara, T.; Silver, M.; Bauters, C.; Masuda, H.; Kalka, C.; Kearney, M.; Chen, D.; Symes, J.F.; Fishman, M.C.; et al. Endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 1370–1376. [CrossRef] [PubMed]
65. Aicher, A.; Heeschen, C.; Mildner-Rihm, C.; Urbich, C.; Ihling, C.; Technau-Ihling, K.; Zeiher, A.M.; Dimmeler, S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat. Med.* **2003**, *9*, 1370–1376. [CrossRef] [PubMed]
66. Gonzalez-Reyes, R.E.; Nava-Mesa, M.O.; Vargas-Sanchez, K.; Ariza-Salamanca, D.; Mora-Munoz, L. Involvement of Astrocytes in Alzheimer’s Disease from a Neuroinflammatory and Oxidative Stress Perspective. *Front. Mol. Neurosci.* **2017**, *10*, 427. [CrossRef]
67. Hettiarachchi, N.T.; Boyle, J.P.; Dallas, M.L.; Al-Owais, M.M.; Schrag, J.L.; Peers, C. Heme oxygenase-1 derived carbon monoxide suppresses Abeta1–42 toxicity in astrocytes. *Cell Death Dis.* **2017**, *8*, e2884. [CrossRef]
68. Fernandez-Fernandez, S.; Almeida, A.; Bolanos, J.P. Antioxidant and bioenergetic coupling between neurons and astrocytes. *Biochem. J.* **2012**, *443*, 3–11. [CrossRef]
69. Dirmagl, U.; Becker, K.; Meisel, A. Preconditioning and tolerance against cerebral ischaemia: From experimental strategies to clinical use. *Lancet Neurol.* **2009**, *8*, 398–412. [CrossRef]
70. O’Donnell, J.C.; Jackson, J.G.; Robinson, M.B. Transient Oxygen/Glucose Deprivation Causes a Delayed Loss of Mitochondria and Increases Spontaneous Calcium Signaling in Astrocytic Processes. *J. Neurosci.* **2016**, *36*, 7109–7127. [CrossRef]
71. Hayakawa, K.; Esposito, E.; Wang, X.; Terasaki, Y.; Liu, Y.; Xing, C.; Ji, X.; Lo, E.H. Transfer of mitochondria from astrocytes to neurons after stroke. *Nature* **2016**, *535*, 551–555. [CrossRef]
72. Kim, S.; Lee, M.; Choi, Y.K. The Role of a Neurovascular Signaling Pathway Involving Hypoxia-Inducible Factor and Notch in the Function of the Central Nervous System. *Biomol. Ther.* **2020**, *28*, 45–57. [CrossRef] [PubMed]
73. Semenza, G.L. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. *Biochem. J.* **2007**, *405*, 1–9. [CrossRef]
74. Choi, Y.K.; Park, J.H.; Baek, Y.Y.; Won, M.H.; Jeoung, D.; Lee, H.; Ha, K.S.; Kwon, Y.G.; Kim, Y.M. Carbon monoxide stimulates astrocytic mitochondrial biogenesis via L-type Ca2+ channel-mediated PGC-1alpha/ERRalpha activation. *Biochem. Biophys. Res. Commun.* **2016**, *469*, 297–304. [CrossRef]
75. Choi, Y.K.; Kim, C.K.; Lee, H.; Jeoung, D.; Ha, K.S.; Kwon, Y.G.; Kim, K.W.; Kim, Y.M. Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. *J. Biol. Chem.* **2010**, *285*, 32116–32125. [CrossRef]
76. Ramamorthy, P.; Xu, G.; Shi, H. Expression of Hypoxia Inducible Factor 1alpha Is Protein Kinase A-dependent in Primary Cortical Astrocytes Exposed to Severe Hypoxia. *Neurochem. Res.* **2019**, *44*, 258–268. [CrossRef] [PubMed]
77. Bulnes, S.; Argandona, E.G.; Bengoaetxea, H.; Leis, O.; Orbitzar, N.; Lafuente, J.V. The role of eNOS in vascular permeability in ENU-induced gliomas. *Brain Edema XIV*; Springer: Vienna, Austria, 2010; pp. 277–282.
78. Zhu, J.; Song, W.; Li, L.; Fan, X. Endothelial nitric oxide synthase: A potential therapeutic target for cerebrovascular diseases. *Mol. Brain* **2016**, *9*, 30. [CrossRef]
79. Shpro, D.; Morel, N.M. Pericyte physiology. *FASEB J.* **1993**, *7*, 1031–1038. [CrossRef]
80. Gautam, J.; Yao, Y. Roles of Pericytes in Stroke Pathogenesis. *Cell Transplant.* **2018**, *27*, 1798–1808. [CrossRef]
81. Liu, S.; Agalliu, D.; Yu, C.; Fisher, M. The role of pericytes in blood-brain barrier function and stroke. *Curr. Pharm. Des.* **2012**, *18*, 3653–3662. [CrossRef]
82. Peppiatt, C.M.; Howarth, C.; Mobbis, P.; Attwell, D. Bidirectional control of CNS capillary diameter by pericytes. *Nature* **2006**, *443*, 700–704. [CrossRef]
83. Horii, S.; Ohtsuki, S.; Hosoya, K.; Nakashima, E.; Terasaki, T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. *J. Neurochem.* **2004**, *89*, 503–513. [CrossRef]
84. Augustin, H.G.; Koh, G.Y.; Thurston, G.; Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10, 165–177. [CrossRef] [PubMed]

85. Hsuan, Y.C.; Lin, C.H.; Chang, C.P.; Lin, M.T. Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke. Brain Behav. 2016, 6, e00526. [CrossRef] [PubMed]

86. Han, D.; Liu, H.; Gao, Y. The role of peripheral monocytes and macrophages in ischemic stroke. Neural. Sci. 2020, 41, 3589–3607. [CrossRef] [PubMed]

87. Sheikh, A.M.; Nagai, A.; Wakabayashi, K.; Narantuya, D.; Kobayashi, S.; Yamaguchi, S.; Kim, S.U. Mesenchymal stem cell transplantation modulates neuroinflammation in focal cerebral ischemia: Contribution of fractalkine and IL-5. Neurobiol. Dis. 2011, 41, 717–724. [CrossRef] [PubMed]

88. Hiratsuka, S.; Minowa, O.; Kuno, J.; Noda, T.; Shibuuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 1998, 95, 9349–9354. [CrossRef]

89. Maki, T.; Choi, Y.K.; Miyamoto, N.; Shindo, A.; Liang, A.C.; Ahn, B.J.; Mandeville, E.T.; Kaji, S.; Itoh, K.; See, J.H.; et al. A-kinase Anchor Protein 12 Is Required for Oligodendrocyte Differentiation in Adult White Matter. Stem Cells 2018, 36, 751–760. [CrossRef]

90. Maki, T.; Moranco, A.; Martinez-San Segundo, P.; Hayakawa, K.; Takase, H.; Liang, A.C.; Gabriel-Salazar, M.; Medina-Gutierrez, E.; Washida, K.; Montaner, J.; et al. Endothelial Progenitor Cell Secretome and Oligovascular Repair in a Mouse Model of Prolonged Cerebral Hypoperfusion. Stroke 2018, 49, 1003–1010. [CrossRef]

91. Hayakawa, K.; Seo, J.H.; Pham, L.D.; Miyamoto, N.; Som, A.T.; Guo, S.; Kim, K.W.; Lo, E.H.; Ariu, K. Cerebral endothelial derived vascular endothelial growth factor promotes the migration but not the proliferation of oligodendrocyte precursor cells in vitro. Neurosci. Lett. 2012, 513, 42–46. [CrossRef]

92. Esposito, E.; Hayakawa, K.; Ahn, B.J.; Chan, S.J.; Xing, C.; Liang, A.C.; Kim, K.W.; Ariu, K.; Lo, E.H. Effects of ischemic post-conditioning on neuronal VEGF regulation and microglial polarization in a rat model of focal cerebral ischemia. J. Neurochem. 2018, 146, 160–172. [CrossRef]

93. Liao, S.; Luo, C.; Cao, B.; Hu, H.; Wang, S.; Yue, H.; Chen, L.; Zhou, Z. Endothelial Progenitor Cells for Ischemic Stroke: Update on Basic Research and Application. Stem Cells Int. 2017, 2017, 2193432. [CrossRef]

94. Choi, Y.K.; Kim, Y.M. Regulation of Endothelial and Vascular Functions by Carbon Monoxide via Crosstalk with Nitric Oxide. Front. Cardiovasc. Med. 2021, 8, 649630. [CrossRef] [PubMed]

95. Choi, Y.K.; Maki, T.; Mandeville, E.T.; Koh, S.H.; Hayakawa, K.; Ariu, K.; Kim, Y.M.; Whalen, M.J.; Xing, C.; Wang, X.; et al. Dual effects of carbon monoxide on pericytes and neurogenesis in traumatic brain injury. Nat. Med. 2016, 22, 1335–1341. [CrossRef]

96. Wang, F.; Tang, H.; Zhu, J.; Zhang, J.H. Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke. Cell Transplant. 2018, 27, 1825–1834. [CrossRef]

97. Cunningham, C.J.; Redondo-Castro, E.; Allan, S.M. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J. Cereb. Blood Flow Metab. 2018, 38, 1276–1292. [CrossRef]

98. Chelluboina, B.; Nalamolu, K.R.; Mendez, G.G.; Klopfenstein, J.D.; Pinson, D.M.; Wang, D.Z.; Veeravalli, K.K. Mesenchymal Stem Cell Treatment Prevents Post-Stroke Dysregulation of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases. Cell Physiol. Biochem. 2017, 44, 1360–1369. [CrossRef]

99. Sheikh, A.M.; Yano, S.; Mitaki, S.; Haque, M.A.; Yamaguchi, S.; Nagai, A. A Mesenchymal stem cell line (B10) increases efficacy in stroke treatment. Cytotherapy 2019, 21, 1825–1834. [CrossRef]

100. Liu, K.; Guo, L.; Zhou, Z.; Pan, M.; Yan, C. Mesenchymal stem cells transfer mitochondria into cerebral microvasculature and promote recovery from ischemic stroke. Microvasc. Res. 2019, 123, 74–80. [CrossRef] [PubMed]

101. Hiasa, K.; Ishibashi, M.; Ohtani, K.; Inoue, S.; Zhao, Q.; Kitamoto, S.; Sata, M.; Ichiki, T.; Takeshita, A.; Egashira, K. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004, 109, 2454–2461. [CrossRef]

102. Tobin, M.K.; Stephen, T.K.L.; Lopez, K.L.; Perdande, M.R.; Bartholomew, A.M.; Cologna, S.M.; Lazarov, O. Activated Mesenchymal Stem Cells Induce Recovery Following Stroke Via Regulation of Inflammation and Oligodendrogenesis. J. Am. Heart Assoc. 2020, 9, e015583. [CrossRef]

103. Yuan, X.; Rosenberg, J.T.; Liu, Y.; Grant, S.C.; Ma, T. Aggregation of human mesenchymal stem cells enhances survival and efficacy in stroke treatment. Cytotherapy 2019, 21, 1033–1048. [CrossRef] [PubMed]

104. Nagasawa-Masuda, A.; Terai, K. ERK activation in endothelial cells is a novel marker during neovascularogenesis. Genes Cells 2016, 21, 1164–1175. [CrossRef] [PubMed]

105. Gao, X.; Wu, D.; Dou, L.; Zhang, H.; Huang, L.; Zeng, J.; Zhang, Y.; Yang, C.; Li, H.; Liu, L.; et al. Protective effects of mesenchymal stem cells overexpressing extracellular regulating kinase 1/2 against stroke in rats. Brain Res. Bull. 2019, 149, 42–52. [CrossRef]

106. Son, J.W.; Park, J.; Kim, Y.E.; Ha, J.; Park, D.W.; Chang, M.S.; Koh, S.H. Glia-Like Cells from Late-Passage Human MSCs Protect Against Ischemic Stroke Through IGFBP-4. Mol. Neurobiol. 2019, 56, 7617–7630. [CrossRef]
109. Park, H.W.; Lim, M.J.; Jung, H.; Lee, S.P.; Paik, K.S.; Chang, M.S. Human mesenchymal stem cell-derived Schwann cell-like cells exhibit neurotrophic effects, via distinct growth factor production, in a model of spinal cord injury. Glia 2010, 58, 1118–1132. [CrossRef] [PubMed]

110. Xia, Y.; Ling, C.; Hu, G.; Zhu, Q.; Zhang, J.; Li, Q.; Zhao, B.; Wang, Y.; Deng, Z. Small extracellular vesicles secreted by human iPSC-derived MSC enhance angiogenesis through inhibiting STAT3-dependent autophagy in ischemic stroke. Stem Cell Res. Ther. 2020, 11, 313. [CrossRef]

111. Bang, O.Y.; Lee, J.S.; Lee, P.H.; Lee, G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 2005, 57, 874–882. [CrossRef]

112. Jaillard, A.; Hommel, M.; Moisan, A.; Zeffiro, T.A.; Favre-Wiki, I.M.; Barbieux-Guillot, M.; Vadot, W.; Marcel, S.; Lamalle, L.; Grand, S.; et al. Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: A Randomized Clinical Trial. Transl. Stroke Res. 2020, 11, 910–923. [CrossRef] [PubMed]

113. Honmou, O.; Hokuin, K.; Matsunaga, T.; Niitsu, Y.; Ishiai, S.; Onodera, R.; Waxman, S.G.; Kocsis, J.D. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011, 134, 1790–1807. [CrossRef] [PubMed]

114. Levy, M.L.; Crawford, J.R.; Dib, N.; Verkh, L.; Tankovich, N.; Cramer, S.C. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke 2019, 50, 2835–2841. [CrossRef]

115. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of progenitor endothelial cells for angiogenesis. Science 1997, 275, 964–967. [CrossRef]

116. Gill, M.; Dias, S.; Hattori, K.; Rivera, M.L.; Hicklin, D.; Witte, L.; Tankovich, N.; Cramer, S.C. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke 2019, 50, 2835–2841. [CrossRef] [PubMed]

117. Powell, T.M.; Paul, J.D.; Verkh, L.; Tankovich, N.; Cramer, S.C. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke 2019, 50, 2835–2841. [CrossRef] [PubMed]

118. Levy, M.L.; Crawford, J.R.; Dib, N.; Verkh, L.; Tankovich, N.; Cramer, S.C. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke 2019, 50, 2835–2841. [CrossRef] [PubMed]

119. Liu, X.; Duan, B.; Cheng, Z.; Jia, X.; Mao, L.; Fu, H.; Che, Y.; Ou, L.; Liu, L.; Kong, D. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein. Cell 2011, 2, 845–854. [CrossRef]

120. Cheng, X.; Wang, H.; Zhang, X.; Zhao, S.; Zhou, Z.; Mu, X.; Zhao, C.; Teng, W. The Role of SDF-1/CXCR4/CXCR7 in Neuronal Regeneration after Cerebral Ischemia. Front. Neurosci. 2017, 11, 590. [CrossRef]

121. Fan, Y.; Shen, F.; Frenzel, T.; Zhu, W.; Ye, J.; Liu, J.; Chen, Y.; Su, H.; Young, W.L.; Yang, G.Y. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann. Neurol. 2010, 67, 488–497. [CrossRef]

122. Bai, Y.Y.; Peng, X.G.; Wang, L.S.; Li, Z.H.; Wang, Y.C.; Lu, C.Q.; Ding, J.; Li, P.C.; Zhao, Z.; Ju, S.H. Bone Marrow Endothelial Progenitor Cell Transplantation After Ischemic Stroke: An Investigation Into Its Possible Mechanism. CNS Neurosci. Ther. 2015, 21, 877–886. [CrossRef]

123. Rosell, A.; Morancho, A.; Navarro-Sobrino, M.; Martinez-Saez, E.; Hernandez-Guillamon, M.; Lope-Piedrafita, S.; Barcelo, V.; Borras, F.; Penalba, A.; Garcia-Bonilla, L.; et al. Factors secreted by endothelial progenitor cells enhance neurorepair responses after cerebral ischemia in mice. PloS ONE 2013, 8, e73244. [CrossRef]

124. Sebastia, J.; Kieran, D.; Breen, B.; King, M.A.; Netteland, D.F.; Joyce, D.; Fitzpatrick, S.F.; Taylor, C.; Prehn, J.H. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ. 2009, 16, 1238–1247. [CrossRef]

125. Man, A.J.; Kujawski, G.; Burns, T.S.; Miller, E.N.; Fierro, F.A.; Leach, J.K.; Bannerman, P. Neurogenic potential of engineered mesenchymal stem cells overexpressing VEGF. Cell Mol. Bioeng. 2016, 9, 96–106. [CrossRef]

126. Akita, T.; Murohara, T.; Ikeda, H.; Sasaki, K.; Shimada, T.; Egami, K.; Imaiizu, T. Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab. Investig. 2003, 83, 65–73. [CrossRef] [PubMed]

127. Banerjee, S.; Bentley, P.; Hamady, M.; Marley, S.; Davis, J.; Shiela, A.; Nicholls, J.; Williamson, D.A.; Jensen, S.L.; Gordon, M.; et al. Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke. Stem Cells Transl. Med. 2014, 3, 1322–1330. [CrossRef]

128. Lin, Y.; Zhang, J.C.; Yao, C.Y.; Wu, Y.; Abdelgawad, A.F.; Yao, S.L.; Yuan, S.Y. Critical role of astrocytic interleukin-17A in post-stroke survival and neuronal differentiation of neural precursor cells in adult mice. Cell Death Dis. 2016, 7, e2273. [CrossRef]

129. Wang, P.; Miao, C.Y. NAMPT as a Therapeutic Target against Stroke. Trends Pharmacol. Sci. 2015, 36, 891–905. [CrossRef]

130. Wang, S.N.; Miao, C.Y. Targeting NAMPT as a therapeutic strategy against stroke. Stroke Vasc. Neurol. 2019, 4, 83–89. [CrossRef] [PubMed]

131. Wang, S.; Xing, Z.; Voslter, P.S.; Yin, H.; Li, W.; Zhang, F.; Signore, A.P.; Stellet, R.A.; Gao, Y.; Chen, J. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: Role of enhanced DNA repair. Stroke 2008, 39, 2587–2595. [CrossRef] [PubMed]

132. Wang, P.; Xu, T.Y.; Guan, Y.F.; Tian, W.W.; Vielot, B.; Rui, Y.C.; Zhai, Q.W.; Su, D.F.; Miao, C.Y. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neural. 2011, 69, 360–374. [CrossRef]

133. Kang, Y.S.; Bae, M.K.; Kim, J.Y.; Jeong, J.W.; Yun, I.; Kang, H.O.; Bae, S.K. Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway. Neurosci. Lett. 2011, 504, 121–126. [CrossRef] [PubMed]
134. Kim, S.R.; Bae, S.K.; Choi, K.S.; Park, S.Y.; Jun, H.O.; Lee, J.Y.; Jang, H.O.; Yoon, I.; Yoon, K.H.; Kim, Y.J.; et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem. Biophys. Res. Commun. 2007, 357, 150–156. [CrossRef] [PubMed]

135. Wang, P.; Du, H.; Zhou, C.C.; Song, J.; Liu, X.; Cao, X.; Mehta, J.L.; Shi, Y.; Yu, S.F.; Miao, C.Y. Intracellular NAMPT-NAD+-SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors. Cardiovasc. Res. 2014, 104, 477–488. [CrossRef]

136. Prabhakar, N.R.; Semenza, G.L. Oxygen Sensing and Homeostasis. Physiology 2015, 30, 340–348. [CrossRef]

137. Kim, Y.M.; Pae, H.O.; Park, J.E.; Lee, Y.C.; Woo, J.M.; Kim, N.H.; Choi, Y.K.; Lee, B.S.; Kim, S.R.; Chung, H.T. Heme oxygenase in the regulation of vascular biology: From molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2011, 14, 137–167. [CrossRef] [PubMed]

138. Lee, J.; Kim, K.E.; Choi, D.K.; Jang, J.Y.; Jung, J.J.; Kiyonari, H.; Shioi, G.; Chang, W.; Suda, T.; Mochizuki, N.; et al. Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy. Sci. Transl. Med. 2013, 5, 203ra127. [CrossRef]

139. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732. [CrossRef] [PubMed]

140. Brune, B.; Zhou, J. Hypoxia-inducible factor-1alpha under the control of nitric oxide. Methods Enzymol. 2007, 435, 463–478. [CrossRef]

141. Liu, Y.; Christou, H.; Morita, T.; Laughner, E.; Semenza, G.L.; Kourerbanas, S. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the SRE enhancer. J. Biol. Chem. 1998, 273, 15257–15262. [CrossRef]

142. Cheng, A.; Wang, S.; Cai, J.; Rao, M.S.; Mattson, M.P. Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev. Biol. 2003, 258, 319–333. [CrossRef]

143. Chung, B.H.; Kim, J.D.; Kim, C.K.; Kim, J.H.; Won, M.H.; Lee, H.S.; Dong, M.S.; Ha, K.S.; Kwon, Y.G.; Kim, Y.M. Icariin stimulates angiogenesis by activating the MEK/ERK- and PESK/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem. Biophys. Res. Commun. 2008, 376, 404–408. [CrossRef]

144. Dimmelser, S.; Fleming, I.; Fisslthaler, B.; Herrmann, C.; Busse, R.; Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399, 601–605. [CrossRef] [PubMed]

145. Zhang, Y.; Lee, T.S.; Kolb, E.M.; Sun, K.; Lu, X.; Sladek, F.M.; Kassab, G.S.; Garland, T., Jr.; Shyy, J.Y. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1281–1287. [CrossRef]

146. Li, Y.S.; Shemmer, B.; Stone, E.; Nardi, M.A.; Jonas, S.; Quartermain, D. Neuroprotection by inhaled nitric oxide in a murine stroke model is concentration and duration dependent. Brain Res. 2013, 1507, 134–145. [CrossRef] [PubMed]

147. Terpolilli, N.A.; Kim, S.W.; Thal, S.C.; Kataoka, H.; Zeisig, V.; Nitzsche, B.; Klaesner, B.; Zhu, C.; Schwarzmaier, S.; Meissner, L.; et al. Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circ. Res. 2012, 110, 727–738. [CrossRef] [PubMed]

148. Choi, Y.K.; Por, E.D.; Kwon, Y.G.; Kim, Y.M. Regulation of ROS production and vascular function by carbon monoxide. Oxid. Med. Cell Longev. 2012, 2012, 794237. [CrossRef] [PubMed]

149. Scheiblich, H.; Bicker, G. Regulation of microglial migration, phagocytosis, and neurite outgrowth by HO-1/CO signaling. Dev. Neurobiol. 2015, 75, 854–876. [CrossRef]

150. Mancuso, C.; Capone, C.; Ranieri, S.C.; Fusco, S.; Calabrese, V.; Eboli, M.L.; Preziosi, P.; Galeotti, T.; Pani, G. Bilirubin as an endogenous modulator of neurotrophin redox signaling. J. Neurosci. Res. 2008, 86, 2235–2249. [CrossRef]

151. Dore, S.; Takahashi, M.; Ferris, C.D.; Zakhray, R.; Hester, L.D.; Guastella, D.; Snyder, S.H. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. USA 1999, 96, 2445–2450. [CrossRef]

152. Imuta, N.; Hori, O.; Kitao, Y.; Tabata, Y.; Yoshimoto, T.; Matsuura, T.; Ogawa, S. Hypoxia-mediated induction of heme oxygenase type I and carbon monoxide release from astrocytes protects nearby cerebral neurons from hypoxia-mediated apoptosis. Antioxid. Redox Signal. 2007, 9, 543–552. [CrossRef] [PubMed]

153. Nada, S.E.; Tulsulakar, J.; Shah, Z.A. Heme oxygenase 1-mediated neurogenesis is enhanced by Ginkgo biloba (EGb 761(R)) after permanent ischemic stroke in mice. Mol. Neurobiol. 2014, 49, 945–956. [CrossRef] [PubMed]

154. Parfenova, H.; Leffler, C.W.; Basuroy, S.; Liu, J.; Fedinec, A.L. Antioxidant roles of heme oxygenase, carbon monoxide, and bilirubin in cerebral circulation during seizures. J. Cereb. Blood Flow Metab. 2012, 32, 1024–1034. [CrossRef]

155. Boehning, D.; Moon, C.; Sharma, S.; Kurt, K.J.; Hester, L.D.; Ronnett, G.V.; Shugar, D.; Snyder, S.H. Carbon monoxide neurotransmission activated by CK2 phosphorylation of heme oxygenase-2. Neuron 2003, 40, 129–137. [CrossRef]

156. Motterlini, R.; Otterbein, L.E. The therapeutic potential of heme oxygenase-1 in cardiovascular disease. Nat. Rev. Drug Discov. 2010, 9, 728–743. [CrossRef]

157. Dulak, J.; Dhanasesh, J.; Jozkowicz, A.; Agarwal, A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: Focus on angiogenesis. Circulation 2008, 117, 231–241. [CrossRef]

158. Cudmore, M.; Ahmad, S.; Al-Ani, B.; Fujisawa, T.; Coxall, H.; Chudasama, K.; Devey, L.R.; Wigmore, S.J.; Abbas, A.; Hewett, P.W.; et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115, 1789–1797. [CrossRef] [PubMed]

159. Lin, H.H.; Chen, Y.H.; Chang, P.F.; Lee, Y.T.; Yet, S.F.; Chau, L.Y. Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1. J. Mol. Cell Cardiol. 2008, 45, 44–55. [CrossRef] [PubMed]
160. Lin, H.H.; Lai, S.C.; Chau, L.Y. Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. *J. Biol. Chem.* **2011**, *286*, 3829–3838. [CrossRef]

161. Yang, P.M.; Huang, Y.T.; Zhang, Y.Q.; Hsieh, C.W.; Wung, B.S. Carbon monoxide releasing molecule induces endothelial nitric oxide synthase activation through a calcium and phosphatidylinositol 3-kinase/Akt mechanism. *Vasc. Pharmacol.* **2016**, *87*, 209–218. [CrossRef] [PubMed]

162. Wang, J.; Zhang, D.; Fu, X.; Yu, L.; Lu, Z.; Gao, Y.; Liu, X.; Man, J.; Li, S.; Li, N.; et al. Carbon monoxide-releasing molecule-3 protects against ischemic stroke by suppressing neuroinflammation and alleviating blood-brain barrier disruption. *J. Neuroinflammation* **2018**, *15*, 188. [CrossRef] [PubMed]

163. Lin, C.C.; Yang, C.C.; Hsiao, L.D.; Chen, S.Y.; Yang, C.M. Heme Oxygenase-1 Induction by Carbon Monoxide Releasing Molecule-3 Suppresses Interleukin-1beta-Mediated Neuroinflammation. *Front. Mol. Neurosci.* **2017**, *10*, 387. [CrossRef] [PubMed]

164. Kim, Y.; Park, J.; Choi, Y.K. The Role of Astrocytes in the Central Nervous System Focused on BK Channel and Heme Oxygenase Metabolites: A Review. *Antioxidants* **2019**, *8*, 121. [CrossRef]

165. Nitti, M.; Piras, S.; Brondolo, L.; Marinari, U.M.; Pronzato, M.A.; Furfaro, A.L. Heme Oxygenase 1 in the Nervous System: Does It Favor Neuronal Cell Survival or Induce Neurodegeneration? *Int. J. Mol. Sci.* **2018**, *19*, 2260. [CrossRef]

166. Stifter, J.; Ulbrich, F.; Goebel, U.; Bohringer, D.; Lagreze, W.A.; Biermann, J. Neuroprotection and neuroregeneration of retinal ganglion cells after intravitreal carbon monoxide release. *PLoS ONE* **2017**, *12*, e0188444. [CrossRef] [PubMed]

167. Weinstock, M.; Kirschbaum-Slager, N.; Lazarovici, P.; Bejar, C.; Youdim, M.B.; Shoham, S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. *Ann. N. Y. Acad. Sci.* **2001**, *939*, 148–161. [CrossRef]

168. Sugaya, K.; Youdim, M.B.; Nordberg, A.; Rao, K.S. Neuroprotection and neuroregeneration in Alzheimer’s disease. *Int. J. Alzheimer’s Dis.* **2012**, *2012*, 864138. [CrossRef]